NeuroBo Pharmaceuticals Files 8-K

Ticker: MTVA · Form: 8-K · Filed: Apr 16, 2024 · CIK: 1638287

Neurobo Pharmaceuticals, INC. 8-K Filing Summary
FieldDetail
CompanyNeurobo Pharmaceuticals, INC. (MTVA)
Form Type8-K
Filed DateApr 16, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, filing, pharmaceuticals

TL;DR

NeuroBo Pharma filed an 8-K on 4/16, check for updates.

AI Summary

NeuroBo Pharmaceuticals, Inc. filed an 8-K on April 16, 2024, reporting on other events and financial statements. The company, formerly Gemphire Therapeutics Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector.

Why It Matters

This filing indicates NeuroBo Pharmaceuticals is providing updates on its corporate activities and financial status to the SEC.

Risk Assessment

Risk Level: low — This is a routine filing with no immediate negative or positive financial implications disclosed.

Key Numbers

Key Players & Entities

FAQ

What specific 'Other Events' are being reported by NeuroBo Pharmaceuticals?

The filing indicates 'Other Events' are being reported, but the specific details are not provided in this excerpt.

What is the significance of the 'Financial Statements and Exhibits' being filed?

This suggests that updated financial information or relevant supporting documents are being submitted to the SEC.

When did NeuroBo Pharmaceuticals change its name from Gemphire Therapeutics Inc.?

The date of the name change was March 31, 2015.

What is NeuroBo Pharmaceuticals' primary business sector?

The company is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.

What is the company's principal executive office address?

The principal executive offices are located at 545 Concord Avenue, Suite 210, Cambridge, Massachusetts 02138.

Filing Stats: 616 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-04-16 16:30:27

Key Financial Figures

Filing Documents

01 Other Events

Item 8.01 Other Events. On April 16, 2024, NeuroBo Pharmaceuticals, Inc. (the "Company" ) posted an updated corporate presentation to its website at https://www.neurobopharma.com/events-presentations/presentations , which the Company may use from time to time in communications or conferences. A copy of the corporate presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K (this "Report" ). The information in this Report, including Exhibit 99.1 hereto, is furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act" ), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company's submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD. Exhibit 99.1 hereto contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements .

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Corporate Presentation, dated April 2024 104 Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROBO PHARMACEUTICALS, INC. Date: April 16, 2024 By: /s/ Hyung Heon Kim Hyung Heon Kim President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing